Cargando…
311. Impact of Non-alcoholic Fatty Liver Disease on Clinical Outcomes in Patients with COVID-19
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease with a prevalence up to 30%. NAFLD is strongly associated with components of metabolic syndrome, already recognized as risk factors for worse outcomes in COVID-19. However, the impact of NAFLD on COVID-19 is not w...
Autores principales: | Vrsaljko, Nina, Samadan, Lara, Budimir, Jelena, Topic, Mirjana Balen, Kurelac, Ivan, Vince, Adriana, Papić, Neven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644783/ http://dx.doi.org/10.1093/ofid/ofab466.513 |
Ejemplares similares
-
Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study
por: Vrsaljko, Nina, et al.
Publicado: (2022) -
Association of Immune Semaphorins with COVID-19 Severity and Outcomes
por: Vargovic, Martina, et al.
Publicado: (2023) -
1347. Do Class 3 Semaphorins Play a Role in COVID-19 Outcomes in Patients with Non-alcoholic Fatty Liver Disease?
por: Vargovic, Martina, et al.
Publicado: (2023) -
Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease
por: Papic, Neven, et al.
Publicado: (2022) -
299. Distinct TGF-β1 Patterns in Patients with Sepsis and Non-alcoholic Fatty Liver Disease
por: Papic, Neven, et al.
Publicado: (2023)